# Halve early clinical trial assessment to 14 days

> “Cut by half the initial assessment target for qualifying Phase 1 clinical trials to 14 days.”
>
> — HM Government; Press release (Medicines and Healthcare products Regulatory Agency), 14 October 2026

- **Status:** Promised
- **Status ladder:** Promised → In plan → Legislated → Funded → Delivering → Delivered
- **Policy area:** [Health](https://ledgergov.uk/promises/area/health)
- **Speaker:** [HM Government](https://ledgergov.uk/actor/hm-government)
- **Made on:** 14 October 2026
- **Where:** Press release (Medicines and Healthcare products Regulatory Agency)
- **Cost a year:** No costing published
- **Who it affects:** Those running qualifying Phase 1 clinical trials
- **When:** Not stated
- **Paid for by:** Not stated when it was announced
- **Quote source:** https://www.gov.uk/government/news/mhra-2030-strategy-to-modernise-patient-centred-regulation-for-the-era-of-ai-and-personalised-medicines (checked word for word on 16 October 2026; Open Government Licence v3.0)
- **Last updated:** 16 October 2026
- **Card:** https://ledgergov.uk/promise/uk-phase-1-trials-14-days-2026

## Where it stands

One of the commitments in the 2030 Strategy of the Medicines and Healthcare products Regulatory Agency (MHRA), an executive agency of the Department of Health and Social Care, set out on 14 October 2026. The release does not say which Phase 1 trials qualify, gives no date for the new target and does not tie it to 2030. The card moves when the MHRA starts reporting against the 14-day target.

## Timeline

- 14 October 2026, Promised: The MHRA's 2030 Strategy commits to halving the initial assessment target for qualifying Phase 1 clinical trials to 14 days

## About the cost

No cost has been published.

## Sources

- [Medicines and Healthcare products Regulatory Agency press release, 14 Oct 2026: MHRA 2030 Strategy to modernise patient-centred regulation for the era of AI and personalised medicines](https://www.gov.uk/government/news/mhra-2030-strategy-to-modernise-patient-centred-regulation-for-the-era-of-ai-and-personalised-medicines)

## Checks

- Checked automatically by AI Journalist, not yet verified by an editor.
- Checked by AI Journalist (automated) on 16 October 2026.

---

LedgerGov.UK's own writing (headlines, status notes, cost notes, summaries) is licensed under [Creative Commons Attribution 4.0 (CC BY 4.0)](https://creativecommons.org/licenses/by/4.0/): reuse it, crediting LedgerGov.UK with a link to the card. Official figures are under the [Open Government Licence v3.0](https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/) unless their source says otherwise; quotes from Parliament under the [Open Parliament Licence v3.0](https://www.parliament.uk/site-information/copyright-parliament/open-parliament-licence/); other quotes are short extracts whose rights stay with the speaker. How the numbers and statuses are made: https://ledgergov.uk/method.